The analysis revealed a positive correlation between RFC3 expression and the concentrations of cyclophosphamide and bleomycin, both commonly used in lymphoma treatment (Figs. 9A & 9B), suggesting that elevated RFC3 levels may contribute to resistance against these agents. This evidence concerns the gene RFC3 and lymphoma.